This free online session will highlight patient and research perspectives, innovative clinical study methods, and emerging regulatory approaches

ERDERA announces its 2026 Open Session

As ERDERA marks the end of its second year, the consortium will gather in Coimbra, Portugal, for its third General Assembly Meeting to explore progress, exchange perspectives and shape the work ahead. As part of the event, ERDERA will once again open its doors to a wider audience through the ERDERA Open Session, which will be broadcast live online on 21 October 2026 from 2:30 pm to 5:30 pm CEST.

This year’s session will focus on ultra-rare diseases and the innovative approaches needed to advance research and treatment when very few, or even individual, people are affected. Through inspiring research and patient stories, the session will explore methodological and regulatory innovation, including new approaches to clinical studies.

The discussion will also consider how ERDERA’s N-of-1 and N-of-2 approaches can contribute to this evolving field. By working hand in hand with researchers and patients, ERDERA aims to help translate new ideas and approaches into meaningful improvements in the lives of people living with rare diseases.

Explore the full programme, discover the speakers, and secure your place by registering here.

News & Updates

You might also be interested in

ERDERA will return to the World Orphan Drug Congress Europe with a booth and an interactive pre-conference workshop examining where artificial intelligence can support rare disease research and therapeutic development, and where human expertise remains essential.
March 10 - March 12
Building on the legacy of the RE(ACT) Congress series (now reaching its ninth edition), RE(ACT) continues to serve as a meeting point for scientific innovation and real-world impact.
September 30 @ 1:00 pm - 2:00 pm
This ERDERA webinar will provide an overview of the regulatory and ethical requirements for advanced therapy medicinal product (ATMP) research, with a particular focus on genome editing and paediatric studies in rare diseases.
Model award agreement document setting out the structure, articles and contractual provisions applicable to funded activities.